# REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Source: https://onco.cc/trials/nct05632809/  
OnCo record `nct05632809` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) is a phase 2, interventional study registered as NCT05632809 by M.D. Anderson Cancer Center, with a registry enrolment figure of 39 participants, started 2023-01-10 and due to reach its primary completion in 2027-12-31. Interventions recorded: NKTR-255; Durvalumab. Conditions listed: Lung Cancer. Primary outcome: Overall survival time distribution. Lung eligibility wording from the registry: "Histologic diagnosis of non-small cell lung cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05632809
- Phase: 2
- Setting: REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT05632809: https://clinicaltrials.gov/study/NCT05632809

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [Nektar Therapeutics](https://onco.cc/companies/nektar-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05632809.json